Glisen VM 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg, Metformin 500 mg, and Voglibose 0.2 mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and enhancing peripheral glucose uptake, contributing to improved insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, thereby reducing postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting better compliance and minimizing gastrointestinal side effects commonly associated with immediate-release preparations. Glisen VM 2 is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component. This combination therapy offers a synergistic approach by targeting multiple pathophysiological defects in type 2 diabetes, optimizing glucose regulation and reducing the risk of long-term complications.